Astellas Pharma Inc. is a global pharmaceutical company with a simple vision – to produce exceptional medicines that change tomorrow for patients in need. Headquartered in Tokyo, Astellas was founded in 2005 through the merger of Yamanouchi and Fujisawa, marrying nearly two centuries of collective experience in producing pharmaceutical drugs.
We combine the deep expertise brought by this long heritage with a forward-thinking outlook of a company. At the heart of that outlook is the patient. Now, Astellas employs more than 17,000 people globally and is a world leader in the development of innovative new medicines.
With our ethos of CHANGING TOMORROW™, Astellas is committed to exploring therapeutic areas in which there is a vital need for treatments that improve and lengthen patients’ lives.
We strive to develop therapies that are first-in-class or best-in-class. Treatments that offer patients and their doctors genuine new options for improving care. Our business in Middle East, North Africa and Sub-Saharan Africa is part of the EMEA region, which is headquartered in the United Kingdom.
Please view Astellas Global Code of Conduct here:
Please view Astellas Global Policy Summary / Position Statements here:
We see ourselves on the forefront of healthcare change to turn innovative science into value for patients. We turn changes into opportunities: We create innovative new drugs and medical solutions by leveraging our core capabilities. We go beyond being a Category Leader: We view business opportunities from multiple perspectives and embrace change in order to create a higher value to our patients every day.